EP0664128A4 - Pharmazeutisches mittel zur hemmung der tumornekrosefaktorproduktion. - Google Patents

Pharmazeutisches mittel zur hemmung der tumornekrosefaktorproduktion.

Info

Publication number
EP0664128A4
EP0664128A4 EP93922048A EP93922048A EP0664128A4 EP 0664128 A4 EP0664128 A4 EP 0664128A4 EP 93922048 A EP93922048 A EP 93922048A EP 93922048 A EP93922048 A EP 93922048A EP 0664128 A4 EP0664128 A4 EP 0664128A4
Authority
EP
European Patent Office
Prior art keywords
tumor necrosis
pharmaceutical composition
necrosis factor
inhibiting tumor
factor production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93922048A
Other languages
English (en)
French (fr)
Other versions
EP0664128A1 (de
Inventor
Kenji Irie
Yataka Ueda
Norio Fujiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharmaceuticals Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Publication of EP0664128A1 publication Critical patent/EP0664128A1/de
Publication of EP0664128A4 publication Critical patent/EP0664128A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP93922048A 1992-10-07 1993-10-07 Pharmazeutisches mittel zur hemmung der tumornekrosefaktorproduktion. Withdrawn EP0664128A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP29645792 1992-10-07
JP296457/92 1992-10-07
PCT/JP1993/001443 WO1994007498A1 (en) 1992-10-07 1993-10-07 Pharmaceutical composition for inhibiting tumor necrosis factor production

Publications (2)

Publication Number Publication Date
EP0664128A1 EP0664128A1 (de) 1995-07-26
EP0664128A4 true EP0664128A4 (de) 1997-12-17

Family

ID=17833803

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93922048A Withdrawn EP0664128A4 (de) 1992-10-07 1993-10-07 Pharmazeutisches mittel zur hemmung der tumornekrosefaktorproduktion.

Country Status (4)

Country Link
US (1) US5646154A (de)
EP (1) EP0664128A4 (de)
CA (1) CA2146126A1 (de)
WO (1) WO1994007498A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9610314A (pt) * 1995-09-13 1999-07-06 Takeda Chemical Industries Ltd Imunossupressor processos para prevenir ou tratar doenças autoimunes em mamíferos e prevenir rejeição de enxerto uso de um composto composição farmacêutica e uso da mesma
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
WO1997042820A1 (en) 1996-05-16 1997-11-20 Duke University Tristetraprolin
ATE366250T1 (de) * 1997-04-25 2007-07-15 Janssen Pharmaceutica Nv Chinazolinone die farnesyltransferase hemmen
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
US6184246B1 (en) 1999-07-30 2001-02-06 The United States Of America As Represented By The Secretary Of Agriculture Inhibition of cytokine production by polymethoxylated flavones
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
DE19951702A1 (de) * 1999-10-27 2001-05-03 Aventis Pharma Gmbh Verwendung von 2-Amino-3,4-dihydro-chinazolinen zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von durch ischämischen Zuständen bewirkten Krankheiten
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
DK1339407T3 (da) * 2000-11-28 2006-08-14 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer til behandling af inflammatorisk tarmsygdom
DK2295081T3 (en) 2001-06-26 2019-02-18 Amgen Inc Antibodies to OPGL
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
EP1618094B1 (de) * 2003-04-30 2007-09-05 The Institutes for Pharmaceutical Discovery, LLC Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
DE102005022977A1 (de) * 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
KR20140054433A (ko) * 2006-11-22 2014-05-08 스미또모 가가꾸 가부시끼가이샤 사이토카이닌 신호전달을 저해할 수 있는 물질
UA117296C2 (uk) 2008-07-31 2018-07-10 Сіномікс, Інк. Способи і проміжні сполуки для одержання підсилювачів солодкого смаку
LT3202460T (lt) 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
EP3102567B1 (de) * 2014-02-04 2019-07-17 University of Tennessee Research Foundation Inhibitoren der paxillinfunktion und zugehörige zusammensetzungen und verfahren
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
CN109111426B (zh) * 2017-06-23 2021-12-14 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
BR112021002261A2 (pt) 2018-08-07 2021-05-04 Firmenich Incorporated 2,2-dióxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-substituídos e formulações e usos dos mesmos
BR112022012625A2 (pt) * 2019-12-24 2022-09-06 Carna Biosciences Inc Compostos moduladores de diacilglicerol quinase
WO2021252680A1 (en) * 2020-06-10 2021-12-16 Ideaya Biosciences, Inc. 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
EP0530994A1 (de) * 1991-08-16 1993-03-10 Merck & Co. Inc. Chinazolinderivate als Inhibitoren von reversen Transcriptasen von HIV

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3305553A (en) * 1965-10-18 1967-02-21 Parke Davis & Co 2-aminoquinazoline derivatives
JPS5394040A (en) * 1976-12-06 1978-08-17 Sandoz Ag Coagolation controlling agent for blood platelet
FR2514765A1 (fr) * 1981-10-21 1983-04-22 Sanofi Sa Nouveaux derives de la phenyl-4 quinazoline actifs sur le systeme nerveux central

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
EP0530994A1 (de) * 1991-08-16 1993-03-10 Merck & Co. Inc. Chinazolinderivate als Inhibitoren von reversen Transcriptasen von HIV

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COOMBS ET AL.: "Synthesis and Antiinflammatory Activity of 1-Alkyl-4-aryl-2(1H)-quinazolinones and quinazolinethiones.", J. MED. CHEM., vol. 16, no. 11, 1973, P0C038, pages 1237 - 1245, XP002043570 *
KOMATSU ET AL.: "Novel Auinazoline Derivatives. I. Synthesis and preliminary pharmacological evaluation of an anti-inflammatory agent, SL-537.", ARZNEIM. FORSCH., vol. 22, no. 11, 1972, P0C038, pages 1958 - 1962, XP002043569 *
See also references of WO9407498A1 *
VASSALLI: "The Pathophysiology of Tumor Necrosis Factor.", ANNU. REV. IMMUNOL., vol. 10, 1992, pages 411 - 452, XP000646541 *
YAMAMOTO ET AL.: "Novel Quinazoline Derivatives II. A new anti-inflammatory agent, SL-512", ARZNEIM. FORSCH., vol. 23, no. 9, 1973, pages 1266 - 1271, XP002043568 *

Also Published As

Publication number Publication date
US5646154A (en) 1997-07-08
EP0664128A1 (de) 1995-07-26
WO1994007498A1 (en) 1994-04-14
CA2146126A1 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
EP0664128A4 (de) Pharmazeutisches mittel zur hemmung der tumornekrosefaktorproduktion.
CA2269815A1 (en) Thienopyrimidines having pde v-inhibiting action
CA2201785A1 (en) New carboxylic acid derivatives, their preparation and their use
TW359672B (en) Thienopyrimidines ad phosphodiesterase V antagonists, process for the production thereof and pharmaceutical compositions containing the same
WO2001072728A3 (en) Novel piperazine derivatives
CA2389333A1 (en) Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
CA2227237A1 (en) N-(aroyl)glycine hydroxamic acid derivatives and related compounds
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
CA2194885A1 (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
IL112622A (en) Iminoalkylamino or aminoalkylideneamino camptothecin derivatives, process for their preparation and pharmaceutical compositions containing them
RU93004793A (ru) Производные хиназолина, способ их получения, фармацевтическая композиция на их основе
CA2311922A1 (en) Thienopyrimidines
BG108426A (en) Novel sulfonic acid derivatives
CA2087414A1 (en) Arylcycloalkyl derivatives their production and their use
EP0712844A4 (de) Neue kondensierte carbonsäureverbindung oder ihr salz und ihre medizinische verwendung
GEP20053617B (en) Bridged Piperazine Derivatives
IL112020A0 (en) Arylacetic acid derivatives, their preparation and their use as fungicides
CA2264005A1 (en) Piperazino derivatives as neurokinin antagonists
CA2218887A1 (en) Piperazino derivatives as neurokinin antagonists
EP0342587A3 (de) Thienotriazolodiazepine und ihre pharmazeutische Verwendung
CA2116388A1 (en) Treatment for viral diseases
EP0711773A4 (de)
EP0818439A3 (de) Imid derivate
CA2269128A1 (en) Piperazino derivatives as neurokinin antagonists
CA2118425A1 (en) Benzothiazolesulfonamide derivative, Method for Preparing the Same, and Use Thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950418

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19971031

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19980808